ESMO大会本周重磅开幕；超 4款国产新药出海，翰森、奥赛康、维立志博科伦 ADC新药获批上市 Insight新药周报

动脉网10-19

ESMO大会本周开幕，据Insight数据库统计，10月12日至18日，全球86款创新药研发有新进展，其中1款获批上市，5款申报上市，2款首次启动III期临床，19款启动临床，26款申报临床。境外部分，本周23款药物研发有推进，包括1款首次启动III期临床，9款首次启动临床，8款首次获批临床。本周有4条新药/新适应症在海外主要国家/地区获批，如阿斯利康与安进联合宣布，美国FDA批准Tezspire...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2576825878?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-19 20:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2576825878","market":"us","top_or_hot":-1,"title":"ESMO大会本周重磅开幕；超 4款国产新药出海，翰森、奥赛康、维立志博科伦 ADC新药获批上市 Insight新药周报","media":"动脉网","content":"<div>\n<p>ESMO大会本周开幕，据Insight数据库统计，10月12日至18日，全球86款创新药研发有新进展，其中1款获批上市，5款申报上市，2款首次启动III期临床，19款启动临床，26款申报临床。境外部分，本周23款药物研发有推进，包括1款首次启动III期临床，9款首次启动临床，8款首次获批临床。本周有4条新药/新适应症在海外主要国家/地区获批，如阿斯利康与安进联合宣布，美国FDA批准Tezspire...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESMO大会本周重磅开幕；超 4款国产新药出海，翰森、奥赛康、维立志博科伦 ADC新药获批上市 Insight新药周报</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESMO大会本周重磅开幕；超 4款国产新药出海，翰森、奥赛康、维立志博科伦 ADC新药获批上市 Insight新药周报\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-19 20:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ESMO大会本周开幕，据Insight数据库统计，10月12日至18日，全球86款创新药研发有新进展，其中1款获批上市，5款申报上市，2款首次启动III期临床，19款启动临床，26款申报临床。境外部分，本周23款药物研发有推进，包括1款首次启动III期临床，9款首次启动临床，8款首次获批临床。本周有4条新药/新适应症在海外主要国家/地区获批，如阿斯利康与安进联合宣布，美国FDA批准Tezspire...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b","article_id":"2576825878","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102001380797372ce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2576825878","pubTimestamp":1760875500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"ESMO大会本周开幕，据Insight数据库统计，10月12日至18日，全球86款创新药研发有新进展，其中1款获批上市，5款申报上市，2款首次启动III期临床，19款启动临床，26款申报临床。境外部分，本周23款药物研发有推进，包括1款首次启动III期临床，9款首次启动临床，8款首次获批临床。此外，诺华公布了伊普可泮Ⅲ期最终分析结果。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","INAQU":"INSIGHT ACQUISITION CORP UNIT 1 CL A & 1/2 WT EXP (26/08/2026)","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4534":"瑞士信贷持仓","AMGN":"安进","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4231":"零售房地产信托","LU0058720904.USD":"联博国际健康护理基金A","BK4566":"资本集团","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4080":"零售业房地产投资信托","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","ADC":"艾格里房产","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4581":"高盛持仓","BK4599":"减肥药"},"translate_title":"ESMO conference kicks off big this week; More than 4 domestic new drugs go overseas, Hansoh, Osaikang, and Weilizhi Bokelun ADC new drugs are approved for marketing Insight New Drug Weekly Report","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAQU":1.5,"AMGN":0.9,"ADC":1.5},"content_text":"ESMO大会本周开幕，据Insight数据库统计，10月12日至18日，全球86款创新药研发有新进展，其中1款获批上市，5款申报上市，2款首次启动III期临床，19款启动临床，26款申报临床。境外部分，本周23款药物研发有推进，包括1款首次启动III期临床，9款首次启动临床，8款首次获批临床。本周有4条新药/新适应症在海外主要国家/地区获批，如阿斯利康与安进联合宣布，美国FDA批准Tezspire（特泽利尤单抗皮下注射）新适应症上市，用于治疗成人和12岁以上儿童控制不佳的慢性鼻窦炎伴鼻息肉的附加维持治疗，该药此前已用于重度哮喘附加维持治疗，此次获批基于III期WAYPOINT试验的积极结果。此外，诺华公布了伊普可泮Ⅲ期最终分析结果。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576825878","isCrawlerRequest":true}